TSTeguh Haryo Sasongko

Teguh Haryo Sasongko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Teguh Haryo Sasongko has a total of 154 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bringing Evidence to Life: Cochrane Evidence Translated for Malay-Speaking Population

    by Teguh Haryo Sasongko

    Background: This report describes a 10-year initiative by Cochrane Malaysia to translate Cochrane Plain Language Summaries (PLS) into Bahasa Malaysia, addressing language barriers in access to health evidence. In a multilingual region with limited non-English health resources, this effort promotes health information equity by making evidence-based content more accessible and culturally relevant. The project offers insights for other LMICs seeking to localize global research and reduce linguistic exclusion in health communication. Objective: To present the processes, outputs, and impact of the Cochrane Bahasa Malaysia Translation Project from its inception in 2015 through 2024, and to share lessons relevant to improving evidence accessibility in similar contexts. Methods: Using a volunteer-driven model coordinated through institutional leadership, the project translated, reviewed, and published PLS into Bahasa Malaysia via www.cochrane.org/ms. Quality control, training, and terminology harmonization were integral to the model. Results: As of December 2024, 4,657 Bahasa Malaysia PLS had been published, reaching a cumulative 6.8 million page views. The project has sustained a steady output of 400-900 translations per year since 2019, with continuous volunteer engagement, editorial consistency, and active collaboration with Cochrane Multi-lingual Programme team. Conclusion: The project demonstrates a scalable model for translating high-quality health evidence into local languages. It also illustrates how volunteer networks, institutional backing, and structured coordination can drive meaningful access to knowledge and support health literacy in LMICs. Its success provides a replicable framework for other regions seeking to localize evidence-based health information.

  • Open Access

    The ASEAN genome consortium: advancing equitable precision medicine through regional solidarity

    by Teguh Haryo Sasongko, Gunadi, Boon Peng Hoh, Jusaku Minari, Shih Wee Seow, Vorasuk Shotelersuk


  • Open Access

    Roles of microRNAs in thalassemia: Mechanisms, biomarkers, and therapeutic implications – a narrative review

    by Lantip Rujito, Tirta Wardana, Joko Mulyanto, Ita Margaretha Nainggolan, Teguh Haryo Sasongko

    Thalassemia, a kind of hemoglobin disorder, affects more than 1.5% of people worldwide. Small RNA molecules, known as microRNAs (miRNAs), are factors in controlling gene production, including hemoglobin production and disease development. This comprehensive review delves into the functions of miRNAs in the pathophysiology of thalassemia. The miRNAs miR-16 and miR-222 have been found to influence the dysregulation of erythropoiesis. These miRNAs act in impeding normal erythropoiesis, resulting in inefficient red blood cell (RBC) production and the premature demise of erythroid progenitor cells. Moreover, other miRNAs like miR-150, miR-210, and miR-485-3p regulate iron levels by pointing molecules such as transferrin receptor 1 (TfR1), ferritin, and hepcidin, which can worsen iron overload issues. Additionally, certain miRNAs have been recognized as markers for the identification of complications related to transfusions in individuals with thalassemia. The miRNAs like miR-451a, miR-20a, and miR-21 are associated with conditions such as iron overload and liver damage. Strategies involving the manipulation of the RNA molecules through mimics or inhibitors show promise in rebalancing gene activity and alleviating symptoms associated with thalassemia based on clinical trials conducted previously. The current review sheds light on how these miRNAs play a key role in modulating immune responses, and stress levels, along with organ-specific issues like heart or liver problems in patients with thalassemia. The miRNAs, including those mentioned above, impact immune cell performance, inflammation processes, and fibrosis development, contributing to the emergence of complications following transfusions. In conclusion, this comprehensive narrative review underlines the critical role of miRNAs in the pathogenesis of thalassemia. The findings illuminate their multifaceted potential as diagnostic biomarkers, therapeutic capacities, and cornerstones for developing tailored medical approaches. By harnessing these insights, clinicians and researchers may revolutionize thalassemia management, significantly improving patients’ health outcomes and quality of life.


  • Open Access

    Potential Use of MicroRNA Technology in Thalassemia Therapy

    by Lantip Rujito, Tirta Wardana, Wahyu Siswandari, Ita Margaretha Nainggolan, Teguh Haryo Sasongko

    Thalassemia encompasses a group of inherited hemoglobin disorders characterized by reduced or absent production of the α- or β-globin chains, leading to anemia and other complications. Current management relies on lifelong blood transfusions and iron chelation, which is burdensome for patients. This review summarizes the emerging therapeutic potential of modulating microRNAs (miRNAs) to treat thalassemia. MiRNAs are small non-coding RNAs that regulate gene expression through sequence-specific binding to messenger RNAs (mRNAs). While they commonly repress gene expression by binding to the 3' untranslated regions (UTRs) of target mRNAs, miRNAs can also interact with 5'UTRs and gene promoters to activate gene expression. Many miRNAs are now recognized as critical regulators of erythropoiesis and are abnormally expressed in β-thalassemia. Therapeutically restoring levels of deficient miRNAs or inhibiting overexpression through miRNA mimics or inhibitors (antagomir), respectively, has shown preclinical efficacy in ameliorating thalassemic phenotypes. The miR-144/451 cluster is especially compelling for targeted upregulation to reactivate fetal hemoglobin synthesis. Advances in delivery systems are addressing previous challenges in stability and targeting of miRNA-based drugs. While still early, gene therapy studies suggest combinatorial approaches with miRNA modulation may provide synergistic benefits. Several key considerations remain including enhancing delivery, minimizing off-target effects, and demonstrating long-term safety and efficacy. While no miRNA therapies have yet progressed to clinical testing for thalassemia specifically, important lessons are being learned through clinical trials for other diseases and conditions, such as cancer, cardiovascular diseases, and viral. If limitations can be overcome through multi-disciplinary collaboration, miRNAs hold great promise to expand and transform treatment options for thalassemia in the future by precisely targeting pathogenic molecular networks. Ongoing innovations, such as advancements in miRNA delivery systems, improved targeting mechanisms, and enhanced understanding of miRNA biology, continue to drive progress in this emerging field towards realizing the clinical potential of miRNA-based medicines for thalassemia patients.


  • Open Access

    Bibliometric analysis and network visualization on Tuberous Sclerosis Complex

    by Ninie Nadia Zulkipli, Idris Long, Habibah A Wahab, Teguh Haryo Sasongko, Asma Hayati Ahmad, Zahiruddin Othman, Aidi Ahmi, Rahimah Zakaria

    Background: Tuberous sclerosis complex (TSC) is a rare autosomal dominant multisystem disease resulting from hyperactivation of the mammalian target of rapamycin (mTOR) signaling pathway. This study aimed to measure the quantitative impact of publications in TSC. Materials and methods: We analysed TSC literature obtained from the Scopus database using Bibliometrix R Package and VOSviewer software. Annual publication trends, most productive and collaborative authors/institutions/ countries, most cited articles, most popular journals and author’s keywords were presented using standard bibliometric indicators. Results and discussion: A total of 5375 documents on TSC were published from 1960 to December 2020, with an increasing trend. The three primary contributing writers were Curatolo P, Kwiatkowski DJ, and Thiele EA, with the United States and its institutions being the largest contributor. The research identified two of the most referenced papers as TSC’s seminal pieces. The top journals that published TSC research were medical journals, namely Journal of Child Neurology, Epilepsia, and Pediatric Neurology. mTOR inhibitor, everolimus, sirolimus, mTORC1, mTOR pathway, autophagy, inflammation, infant, intellectual disability, white matter, TSC-associated neuropsychiatric disorders, TOSCA and quality of life were relatively newer author’s keywords and may indicate the future research hotspots in TSC research. Conclusion: Over the last few decades, TSC research has grown in importance, particularly in the field of clinical medicine. Therapeutic components targeting TSC-related pathways, the utilisation of TSC as disease models and long-term safety studies will be future research areas. Bangladesh Journal of Medical Science Vol. 23 No. 01 January’24 Page : 18-28


  • Open Access

    Parental stature as a risk factor for stunting in Indonesia: A systematic review and meta-analysis

    by Mazaya P. Amriviana, Cut Khairunnisa, Teguh H. Sasongko

    Stunting is defined by height of more than two standard deviations below the WorldHealth Organization's (WHO) child growth standard median. It is a significant nutritionalproblem in developing countries, where in 2021, Indonesia recorded a stunting prevalenceat 24.4%, slightly higher than the global prevalence (22%). Reducing the prevalence ofstunting has been the focus of the current administration in the Indonesian government,as delineated in the 2020–2024 National Medium-Term Development Plan. Globally,many studies have addressed parental stature as a risk factor of stunting. However,systematic reviews that summarized and critically appraised the relationship betweenparental stature and the incidence of stunting in Indonesia was scarce. This systematicreview aimed to assess parental stature as a risk factor for stunting among Indonesiantoddlers. Studies were searched through PubMed (MEDLINE), Google Scholar andMendeley. Studies on Indonesian toddlers under five years old living in Indonesia wereincluded. The quality of the included studies was assessed using Joanna Briggs Institute(JBI) critical appraisal tool. Data were extracted using a standardized data extraction formand were analyzed using Cochrane’s RevMan 5.3. Twenty-seven prospective andretrospective cohort, case-control and cross-sectional studies were included with a total4041 children. Out of 27 included studies, eight were found to be of low, seven of moderateand twelve of high quality. The result showed that parental stature was associated with theincidence of stunting among toddlers in Indonesia, either the mother only (odds ratio(OR) 1.92; 95% confidence interval (95%CI: 1.71–2.15), the father only (OR 5.21; 95%CI:1.71–15.86) or both parents (OR 3.01; 95%CI: 2.41–3.75). However, studies on father andboth parental statures suffered from substantial heterogeneity, imprecision and mixedqualities, therefore, they should be cautiously interpreted.


  • Rapamycin and rapalogs for tuberous sclerosis complex

    by Teguh Haryo Sasongko, Kumaraswamy Kademane, Stanley Chai Soon Hou, Tan Xin Yi Jocelyn, Zamh Zabidi-Hussin

    Background Potential benefits of rapamycin or rapalogs for treating people with tuberous sclerosis complex (TSC) have been shown. Currently everolimus (a rapalog) is only approved for TSC‐associated renal angiomyolipoma and subependymal giant cell astrocytoma (SEGA), but not other manifestations of TSC. A systematic review needs to establish evidence for rapamycin or rapalogs for various manifestations in TSC. This is an updated review. Objectives To determine the effectiveness of rapamycin or rapalogs in people with TSC for decreasing tumour size and other manifestations and to assess the safety of rapamycin or rapalogs in relation to their adverse effects. Search methods We identified relevant studies from the Cochrane‐Central‐Register‐of‐Controlled‐Trials (CENTRAL), Ovid MEDLINE and ongoing trials registries with no language restrictions. We searched conference proceedings and abstract books of conferences. Date of the last searches: 15 July 2022. Selection criteria Randomised controlled trials (RCTs) or quasi‐RCTs of rapamycin or rapalogs in people with TSC. Data collection and analysis Two review authors independently extracted data and assessed the risk of bias of each study; a third review author verified the extracted data and risk of bias decisions. We assessed the certainty of the evidence using GRADE. Main results The current update added seven RCTs, bringing the total number to 10 RCTs (with 1008 participants aged 3 months to 65 years; 484 males). All TSC diagnoses were by consensus criteria as a minimum. In parallel studies, 645 participants received active interventions and 340 placebo. Evidence is low‐to‐high certainty and study quality is mixed; mostly a low risk of bias across domains, but one study had a high risk of performance bias (lack of blinding) and three studies had a high risk of attrition bias. Manufacturers of the investigational products supported eight studies. Systemic administration Six studies (703 participants) administered everolimus (rapalog) orally. More participants in the intervention arm reduced renal angiomyolipoma size by 50% (risk ratio (RR) 24.69, 95% confidence interval (CI) 3.51 to 173.41; P = 0.001; 2 studies, 162 participants, high‐certainty evidence). In the intervention arm, more participants in the intervention arm reduced SEGA tumour size by 50% (RR 27.85, 95% CI 1.74 to 444.82; P = 0.02; 1 study; 117 participants; moderate‐certainty evidence) ,and reported more skin responses (RR 5.78, 95% CI 2.30 to 14.52; P = 0.0002; 2 studies; 224 participants; high‐certainty evidence). In one 18‐week study (366 participants), the intervention led to 25% fewer seizures (RR 1.63, 95% CI 1.27 to 2.09; P = 0.0001) or 50% fewer seizures (RR 2.28, 95% CI 1.44 to 3.60; P = 0.0004); but there was no difference in numbers being seizure‐free (RR 5.30, 95% CI 0.69 to 40.57; P = 0.11) (moderate‐certainty evidence). One study (42 participants) showed no difference in neurocognitive, neuropsychiatry, behavioural, sensory and motor development (low‐certainty evidence). Total adverse events (AEs) did not differ between groups (RR 1.09, 95% CI 0.97 to 1.22; P = 0.16; 5 studies; 680 participants; high‐certainty evidence). However, the intervention group experienced more AEs resulting in withdrawal, interruption of treatment, or reduced dose (RR 2.61, 95% CI 1.58 to 4.33; P = 0.0002; 4 studies; 633 participants; high‐certainty evidence and also reported more severe AEs (RR 2.35, 95% CI 0.99 to 5.58; P = 0.05; 2 studies; 413 participants; high‐certainty evidence). Topical (skin) administration Four studies (305 participants) administered rapamycin topically. More participants in the intervention arm showed a response to skin lesions (RR 2.72, 95% CI 1.76 to 4.18; P < 0.00001; 2 studies; 187 participants; high‐certainty evidence) and more participants in the placebo arm reported a deterioration of skin lesions (RR 0.27, 95% CI 0.15 to 0.49; 1 study; 164 participants; high‐certainty evidence). More participants in the intervention arm responded to facial angiofibroma at one to three months (RR 28.74, 95% CI 1.78 to 463.19; P = 0.02) and three to six months (RR 39.39, 95% CI 2.48 to 626.00; P = 0.009; low‐certainty evidence). Similar results were noted for cephalic plaques at one to three months (RR 10.93, 95% CI 0.64 to 186.08; P = 0.10) and three to six months (RR 7.38, 95% CI 1.01 to 53.83; P = 0.05; low‐certainty evidence). More participants on placebo showed a deterioration of skin lesions (RR 0.27, 95% CI 0.15 to 0.49; P < 0.0001; 1 study; 164 participants; moderate‐certainty evidence). The intervention arm reported a higher general improvement score (MD ‐1.01, 95% CI ‐1.68 to ‐0.34; P < 0.0001), but no difference specifically in the adult subgroup (MD ‐0.75, 95% CI ‐1.58 to 0.08; P = 0.08; 1 study; 36 participants; moderate‐certainty evidence). Participants in the intervention arm reported higher satisfaction than with placebo (MD ‐0.92, 95% CI ‐1.79 to ‐0.05; P = 0.04; 1 study; 36 participants; low‐certainty evidence), although again with no difference among adults (MD ‐0.25, 95% CI ‐1.52 to 1.02; P = 0.70; 1 study; 18 participants; low‐certainty evidence). Groups did not differ in change in quality of life at six months (MD 0.30, 95% CI ‐1.01 to 1.61; P = 0.65; 1 study; 62 participants; low‐certainty evidence). Treatment led to a higher risk of any AE compared to placebo (RR 1.72, 95% CI 1.10, 2.67; P = 0.02; 3 studies; 277 participants; moderate‐certainty evidence); but no difference between groups in severe AEs (RR 0.78, 95% CI 0.19 to 3.15; P = 0.73; 1 study; 179 participants; moderate‐certainty evidence). Authors' conclusions Oral everolimus reduces the size of SEGA and renal angiomyolipoma by 50%,...


  • Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease

    by Teguh Haryo Sasongko, Srikanth Nagalla

    Background Sickle cell disease is a group of disorders characterized by deformation of erythrocytes. Renal damage is a frequent complication in sickle cell disease as a result of long‐standing anemia and disturbed circulation through the renal medullary capillaries. Due to the improvement in life expectancy of people with sickle cell disease, there has been a corresponding significant increase in the incidence of renal complications. Microalbuminuria and proteinuria are noted to be a strong predictor of subsequent renal failure. There is extensive experience and evidence with angiotensin‐converting enzyme (ACE) inhibitors over many years in a variety of clinical situations for patients who do not have sickle cell disease, but their effect in people with this disease is unknown. It is common practice to administer ACE inhibitors for sickle nephropathy due to their renoprotective properties; however, little is known about their effectiveness and safety in this setting. This is an update of a Cochrane Review first published in 2013 and 2015. Objectives To determine the effectiveness of ACE inhibitor administration in people with sickle cell disease for decreasing intraglomerular pressure, microalbuminuria and proteinuria and to to assess the safety of ACE inhibitors as pertains to their adverse effects. Search methods The authors searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Hameoglobinopathies Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. Date of the most recent search: 18 October 2021. We also searched clinical trial registries. Date of the most recent search: 22 August 2021. Selection criteria Randomized or quasi‐randomized controlled trials of ACE inhibitors designed to reduce microalbuminuria and proteinuria in people with sickle cell disease compared to either placebo or standard treatment regimen. Data collection and analysis Three authors independently applied the inclusion criteria in order to select studies for inclusion in the review. Two authors assessed the risk of bias of studies and extracted data and the third author verified these assessments. Main results Seven studies were identified through the searches. Six studies were excluded. The included study randomized 22 participants (7 males and 15 females) having proteinuria or microalbuminuria with sickle cell disease and treated the participants for six months (median length of follow up of three months) with captopril or placebo. Overall, the certainty of the evidence provided in this review was very low, since most risk of bias domains were judged to have either an unclear or a high risk of bias. Because of this, we are uncertain whether captopril makes any difference, in total urinary albumin excretion (at six months) as compared to the placebo group, although it yielded a mean difference of ‐49.00 (95% confidence interval (CI) ‐124.10 to 26.10) or in the absolute change score, although it yielded a mean difference of ‐63.00 (95% CI ‐93.78 to ‐32.22). At six months albumin excretion in the captopril group was noted to decrease from baseline by a mean (standard deviation) of 45 (23) mg/day and the placebo group was noted to increase by 18 (45) mg/day. Serum creatinine and potassium levels were reported constant throughout the study (very low‐certainty evidence). The potential for inducing hypotension should be highlighted; the study reported a decrease of 8 mmHg in systolic pressure and 5 mmHg in diastolic and mean blood pressure (very low‐certainty evidence). Authors' conclusions Overall, we judged the certainty of the evidence to be very low. The included study selectively reported its results, was not powered to detect a group difference, should it exist, and otherwise did not offer enough information to allow us to judge the bias inherent in the study. Indirectness (in relation to the limited age and type of population included) and imprecision (wide confidence intervals around the effect estimate) were observed. More long‐term studies involving multiple centers and larger cohorts using a randomized‐controlled design are warranted, especially among the pediatric age group. Detailed reporting of each outcome measure is necessary to allow a clear cut interpretation in a systematic review. One of the difficulties encountered in this review was the lack of detailed data reported in the included study. Overall, we judged the certainty of this evidence to be very low.


  • Antiphospholipid antibodies in epilepsy: A systematic review and meta-analysis

    by Asiful Islam, Fahmida Alam, Cinzia Cavestro, Cornelia Calcii, Teguh Haryo Sasongko, Roger A. Levy, Siew Hua Gan